Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fampridine add-on to risperidone for negative symptoms in schizophrenia
IRCT20090117001556N163Phase 3Recruiting
- Sponsor
- Tehran University of Medical Sciences
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dalfampridine in schizophrenia (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoint: Severity of schizophrenia. Started Sep 2025; status: recruiting.
02
Drugs
dalfampridine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20090117001556N163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090117001556N163.